Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis

Clinical Cancer Research

Volumn 18, Issue 13, 2012, Pages 3580-3591

  Chan, Christine M ^a,b,c   Jing, Xia ^a   Pike, Laura A ^a   Zhou, Qiong ^a   Lim, Dong Jun ^a,d   Sams, Sharon B ^a   Lund, Gregory S ^a   Sharma, Vibha ^a   Haugen, Bryan R ^a   Schweppe, Rebecca E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Children's Hospital Colorado   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; THYROID PAPILLARY CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FOCAL ADHESION KINASE 1; HUMANS; MALE; MICE; MICE, NUDE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIMIDINES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES; THYROID NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863335331     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3359     Document Type: Article

References (50)

1. Pfister DG, Fagin JA. Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol 2008;26:4701-4.
2. Haugen BR, Kane MA. Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab 2010;95:987-93.
3. Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 2009;23:713-22.
4. Kopetz S, Shah AN, Gallick GE. Src continues aging: current and future clinical directions. Clin Cancer Res 2007;13:7232-6.
5. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 1993;91:53-60. (Pubitemid 23037252)
6. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-42.
7. Bolen JB, Veillette A, Schwartz AM, Deseau V, Rosen N. Analysis of pp60c-src in human colon carcinoma and normal human colon mucosal cells. Oncogene Res 1987;1:149-68. (Pubitemid 18072623)
8. Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Luhrs H, Friess H, et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 1998;243:503-8. (Pubitemid 28414054)
9. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-58. (Pubitemid 36791891)
10. Cartwright CA, Meisler AI, Eckhart W. Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci U S A 1990;87:558-62.
11. Stein PL, Vogel H, Soriano P. Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. Genes Dev 1994;8:1999-2007.
12. Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003;63:5028-33. (Pubitemid 37022641)
13. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64:693-702. (Pubitemid 121001157)
14. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, et al. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 2011;17:1713-21.
15. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, et al. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 2010;70:2296-306.
16. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323-33.
17. Goldenberg-Furmanov M, Stein I, Pikarsky E, Rubin H, Kasem S, Wygoda M, et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res 2004;64:1058-66. (Pubitemid 38176910)
18. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6:834-48. (Pubitemid 47500507)
19. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl) ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 2006;49:6465-88. (Pubitemid 44657442)
20. Kim LC, Rix U, Haura EB. Dasatinib in solid tumors. Expert Opin Investig Drugs 2010;19:415-25.
21. Rucci N, Susa M, Teti A. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem 2008;8:342-9. (Pubitemid 351761438)
22. Kim SJ, Park JW, Yoon JS, Mok JO, Kim YJ, Park HK, et al. Increased expression of focal adhesion kinase in thyroid cancer: immunohistochemical study. J Korean Med Sci 2004;19:710-5. (Pubitemid 39452129)
23. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa R, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion Kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009;94:2199-203.
24. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008;93:4331-41. (Pubitemid 352789529)
25. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009;16:67-78.
26. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112-6.
27. Schweppe R, Kerege A, Sharma V, Poczobutt J, Gutierrez-Hartmann A, Grzywa R, et al. Distinct genetic alterations in the MAPK pathway dictate sensitivity of thyroid cancer cells to MKK1/2 inhibition. Thyroid 2009;19:825-35.
28. Kim S, Park YW, Schiff BA, Doan DD, Yazici Y, Jasser SA, et al. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res 2005;11:1713-21. (Pubitemid 40471832)
29. Ahn SH, Henderson Y, Kang Y, Chattopadhyay C, Holton P, Wang M, et al. An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg 2008;134:190-7. (Pubitemid 351287501)
30. Wood W, Sharma V, Bauerle K, Pike L, Zhou Q, Fretwell D, et al. PPARgamma promotes growth and invasion of thyroid cancer cells. PPAR Res 2011;2011:171765.
31. Kang Y. Analysis of cancer stem cell metastasis in xenograft animal models. Methods Mol Biol 2009;568:7-19.
32. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61. (Pubitemid 40053752)
33. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11:6924-32. (Pubitemid 41428750)
34. Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in threedimensional environments. Cancer Biol Ther 2010;9:764-77.
35. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 2009;119:252-66.
36. Ishibe S, Joly D, Liu ZX, Cantley LG. Paxillin serves as an ERKregulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis. Mol Cell 2004;16:257-67. (Pubitemid 39388840)
37. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, et al. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 2009;15:6852-61.
38. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res 2009;69:1958-65.
39. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007;6:1962-72. (Pubitemid 47052486)
40. Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther 2010;9:2322-32.
41. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
42. Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 2009;27:77-83.
43. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010;6:291-9.
44. Emaduddin M, Bicknell DC, Bodmer WF, Feller SM. Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. Proc Natl Acad Sci U S A 2008;105:2358-62. (Pubitemid 351520518)
45. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007;67:2800-8. (Pubitemid 46548969)
46. Chan D, Tyner JW, Chng WJ, BI C, Okamoto R, Said J, et al. Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo. Oncol Lett 2012;3:807-15.
47. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9. (Pubitemid 41507982)
48. Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, et al. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006;5:3014-22. (Pubitemid 46092042)
49. Ammer AG, Kelley LC, Hayes KE, Evans JV, Lopez-Skinner LA, Martin KH, et al. Saracatinib impairs head and neck squamous cell carcinoma invasion by disrupting invadopodia function. J Cancer Sci Ther 2009;1:52-61.
50. Ringel MD. Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier. Thyroid 2011;21:487-92.